Shanghai JMT-Bio Inc.
42
14
15
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 42 trials
100.0%
+13.5% vs industry average
29%
12 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (42)
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Role: lead
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Role: lead
SYS6090 Combination Therapy in Advanced Lung Cancer
Role: lead
Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants
Role: lead
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Role: lead
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Role: lead
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Role: lead
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Role: lead
a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia
Role: lead
JMT106 Injection in the Treatment of Advanced Solid Tumors
Role: lead
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Role: lead
A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy
Role: lead
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
Role: lead
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Role: lead
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Role: lead
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Role: lead
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Role: lead
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Role: lead
JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Role: lead
A Study of JMT203 in Patients With Cancer Cachexia
Role: lead